Dynogen, Apex Bioventures Acquisition Corp. deal

Special purpose acquisition company Apex will acquire Dynogen for $98 million in stock. Dynogen's shareholders will receive 13.5 million Apex shares for a 56% stake in the combined company, which will keep the name Dynogen and is expected to continue to trade on the American Stock Exchange. Dynogen shareholders also are eligible for two milestone payments, each worth up to $23 million in Apex stock. The combined company is expected to have about $65 million in cash. ...